Nuvalent, Inc.

NASDAQ:NUVL

Biotechnology

Healthcare
$123.96 -0.02%

-$0.03 today

Market cap
$9.13B
Beta
1.15
P/E (TTM)
-21.6
EPS (TTM)
-$5.72
52W Low $71.13High $123.62

Volume 0.00M

Average 1.91M

NUVL Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Nuvalent, Inc.NASDAQ: NUVL

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q1 FY2026 selling, general & admin of $35.8M rose 75.5% year over year, behind the +77.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 4.0% from the prior quarter. Over 3 fiscal years it compounded at +68.6% a year.

Context

  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 11 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +71.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$35.8M+4.0% QoQ
Last fiscal yearDec 2025
$107.34M+71.5% YoY
LTMMar 2026
$122.74M+77.8% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+75.5%-100.0%-175.5 pp
1 year+71.5%-100.0%-171.5 pp
3-year CAGR+68.6%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
107.34M USD
Year-over-year change
+71.5%
4-year CAGR
+79.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How NUVL compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +77.8% is the 2nd highest of 9, against a peer median of +49.2%.
  • Over three fiscal years its annual growth of +68.6% compares with a peer median of +29.5%.
NUVL Competitors
Selling, General & Admin for NUVL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JAZZJazz Pharmaceuticals plcLTM Sep 2026$1.56B USD-12.2%+8.5%33.0%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$712.67M USD+55.0%+53.0%91.8%
CYTKCytokinetics, IncorporatedLTM Jun 2026$370.47M USD+53.0%+16.9%522.1%
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026$255.27M USD+45.4%+28.4%90.9%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$201.04M USD+64.9%+30.5%44.6%
PCVXVaxcyte, Inc.LTM Jun 2026$132.67M USD+14.1%+48.1%—
NUVLNuvalent, Inc.LTM Mar 2026$122.74M USD+77.8%+68.6%—
ABVXAbivax S.A.FY2025€72.87M EUR+87.3%+113.4%—
CRSPCRISPR Therapeutics AGLTM Sep 2026$68.9M USD-6.0%-10.5%273.7%
Peer median (excluding NUVL) —+49.2%+29.5%91.3%

Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development35.56M63.73M113.24M217.77M306.97M
Selling, General & Admin10.26M22.38M36.25M62.59M107.34M
Operating Expenses45.82M86.11M149.49M280.37M414.31M
Depreciation & Amortization215K00280.37M414.31M
EBITDA(46.12M)(81.85M)(126.22M)20.38M(10.49M)
EBITDA Margin—————
Operating Income(45.82M)(86.11M)(149.49M)(280.37M)(414.31M)
Operating Margin—————
Interest Income0023.27M38.32M44.74M
Interest Expense0023.27M00
Other Income / Expenses(521K)4.25M23.27M20.38M(10.49M)
Income Before Tax(46.34M)(81.85M)(126.22M)(259.99M)(424.79M)
Pre-Tax Margin—————
Income Tax Expense000764K585K
Net Income(46.34M)(81.85M)(126.22M)(260.76M)(425.38M)
Net Margin—————
EPS (Basic)(2.13)(1.65)(2.17)(3.93)(5.85)
EPS (Diluted)(2.13)(1.65)(2.17)(3.93)(5.85)
Weighted Avg Shares21.78M49.67M58.22M66.41M72.69M
Weighted Avg Shares (Diluted)21.78M49.67M58.22M66.41M72.69M

Nuvalent, Inc.

NASDAQ:NUVL

Intrinsic Alpha fair value

Locked

Current Price

$123.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.